Combining Serum DNA Methylation Biomarkers and Protein Tumor Markers Improved Clinical Sensitivity for Early Detection of Colorectal Cancer

Table 3

Performance of combining both DNA methylation biomarkers and tumor markers for detecting different disease states.

		mSEPT9+mSDC2	mSEPT9+mSDC2+CEA and mSEPT9+mSDC2+CEA+AFP	mSEPT9+mSDC2+CEA+CA19-9 and mSEPT9+mSDC2+CEA+AFP+CA19-9
Sensitivity (95% CI)	CRC stage
	0+I	35.3 (15.3-61.4)	47.1 (23.9-71.5)
	II	48.6 (31.7-65.7)	74.3 (56.4-86.9)
	III	64.0 (42.6-81.3)	80.0 (58.7-92.4)
	IV	89.7 (71.5-97.3)	96.6 (80.4-99.8)
	All	61.3 (51.3-70.5)	77.4 (68.0-84.7)
	AA	39.3 (22.1-59.3)	39.3 (22.1-59.3)
	CRC+AA	56.7 (47.9-65.2)	69.4 (60.8-76.9)
	SP	30.0 (12.8-54.3)	35.0 (16.3-59.1)	40.0 (20.0-63.6)
Specificity (95% CI)		90.2 (81.8-95.2)	90.2 (81.8-95.2)	89.1 (80.5-94.4)